Ototoxic side-effects of high doses of frusemide in patients with uraemia. - Suppr | 超能文献

文献检索
文档翻译
深度研究
学术资讯

Zotero 插件

邀请有礼
套餐&价格
历史记录

应用&插件

Zotero 插件浏览器插件 Mac 客户端 Windows 客户端微信小程序

定价

高级版会员购买积分包购买API积分包

服务

文献检索文档翻译深度研究 API 文档 MCP 服务

关于我们

关于 Suppr 公司介绍联系我们用户协议隐私条款

关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ototoxic side-effects of high doses of frusemide in patients with uraemia. - Suppr | 超能文献

Ototoxic side-effects of high doses of frusemide in patients with uraemia.

作者信息

Wigand M E, Heidland A

出版信息

Postgrad Med J. 1971 Apr;47:Suppl:54-6.

Abstract

摘要

相似文献

1

Ototoxic side-effects of high doses of frusemide in patients with uraemia.

Postgrad Med J. 1971 Apr;47:Suppl:54-6.

2

[Hearing loss induced by the use of high doses of furosemide in the treatment of uremia].[高剂量呋塞米用于尿毒症治疗所致的听力损失]

Klin Wochenschr. 1970 Sep 1;48(17):1052-6. doi: 10.1007/BF01497211.

3

Deafness associated with oral furosemide.与口服速尿相关的耳聋

South Med J. 1978 Jan;71(1):86-8. doi: 10.1097/00007611-197801000-00029.

4

Transient deafness from high doses of frusemide.大剂量速尿导致的暂时性耳聋。

Br Med J. 1971 Oct 9;4(5779):113-4. doi: 10.1136/bmj.4.5779.113-b.

5

Identification of ototoxic drugs by guinea pig shiver audiometry.

Audiology. 1974;13(4):302-10. doi: 10.3109/00206097409071687.

6

Ototoxicity of intravenous frusemide.静脉注射速尿的耳毒性。

Lancet. 1971 Nov 20;2(7734):1156. doi: 10.1016/s0140-6736(71)91317-1.

7

Deafness following standard intravenous dose of ethacrynic acid.标准静脉剂量依他尼酸导致的耳聋。

JAMA. 1971 May 3;216(5):795-8.

8

Toxic deafness. I. Histological study of the effect of arsenic, salicylates and quinine, on the organ of Corti of guinea pigs.中毒性耳聋。一、砷、水杨酸盐和奎宁对豚鼠柯蒂氏器作用的组织学研究。

J Egypt Med Assoc. 1975;58(3-4):144-57.

9

Permanent deafness associated with furosemide administration.与使用速尿相关的永久性耳聋。

Ann Otol Rhinol Laryngol. 1975 Jan-Feb;84(1 Pt 1):94-101. doi: 10.1177/000348947508400114.

10

Experimental observations on the ototoxicity of nitrogen mustard.

Laryngoscope. 1968 Apr;78(4):530-8. doi: 10.1288/00005537-196804000-00004.

引用本文的文献

1

Hypertension Associated With Hearing Loss and Tinnitus Among Hypertensive Adults at a Tertiary Hospital in South Africa.南非一家三级医院高血压成人患者中与听力损失和耳鸣相关的高血压

Front Neurol. 2022 Mar 16;13:857600. doi: 10.3389/fneur.2022.857600. eCollection 2022.

2

Furosemide use in Italian neonatal intensive care units: a national survey.呋塞米在意大利新生儿重症监护病房的使用：一项全国性调查。

Ital J Pediatr. 2020 Jun 22;46(1):86. doi: 10.1186/s13052-020-00851-2.

3

Hearing consequences in Gjb2 knock-in mice: implications for human p.V37I mutation.

Gjb2基因敲入小鼠的听力后果：对人类p.V37I突变的影响

Aging (Albany NY). 2019 Sep 27;11(18):7416-7441. doi: 10.18632/aging.102246.

4

Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review.早产儿使用呋塞米与感音神经性听力损失及肾钙质沉着症之间的关联：一项系统评价

Matern Health Neonatol Perinatol. 2018 Nov 19;4:23. doi: 10.1186/s40748-018-0092-2. eCollection 2018.

5

Prolonged furosemide exposure and risk of abnormal newborn hearing screen in premature infants.早产儿长期使用呋塞米与新生儿听力筛查异常风险

Early Hum Dev. 2018 Oct;125:26-30. doi: 10.1016/j.earlhumdev.2018.08.009. Epub 2018 Sep 4.

6

Hypertension, Diuretic Use, and Risk of Hearing Loss.高血压、利尿剂的使用与听力损失风险

Am J Med. 2016 Apr;129(4):416-22. doi: 10.1016/j.amjmed.2015.11.014. Epub 2015 Nov 30.

7

Clinical pharmacology of furosemide in neonates: a review.新生儿呋塞米的临床药理学：综述。

Pharmaceuticals (Basel). 2013 Sep 5;6(9):1094-129. doi: 10.3390/ph6091094.

8

Drug-induced tinnitus and other hearing disorders.药物性耳鸣及其他听力障碍。

Drug Saf. 1996 Mar;14(3):198-212. doi: 10.2165/00002018-199614030-00006.

9

Experimental, clinical and preventive aspects of ototoxicity.耳毒性的实验、临床及预防方面

Eur Arch Otorhinolaryngol. 1994;251(7):375-92. doi: 10.1007/BF00181963.

10

Furosemide and ethacrynic acid in acute tubular necrosis.速尿和依他尼酸在急性肾小管坏死中的应用

West J Med. 1980 Aug;133(2):163-70.